Adding Local Consolidative Therapy (LCT) to Osimertinib Significantly Improves PFS in EGFR-Mutated NSCLC

Silevertinib Yields Significant Response Rates in Frontline EGFR Non-Classically–Mutated NSCLC

June 3, 2026

ESAONA Data Support Asandeutertinib as a Frontline Option in EGFR+ NSCLC With Brain Metastases

June 3, 2026

Sequential Erlotinib Plus Ramucirumab Prior to Osimertinib Fails to Improve Outcomes in EGFR L858R–Mutant NSCLC

June 1, 2026

FLAME Study Shows Osimertinib Plus Chemotherapy Improves PFS in ctDNA-Persistent EGFR-Mutant NSCLC

June 1, 2026